Maximizing the renal cyclic 3'-5'-guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: a novel strategy to improve renal function in experimental overt heart failure.
about
Cardiac endothelium-myocyte interaction: clinical opportunities for new heart failure therapies regardless of ejection fractionThe kidney in congestive heart failure: 'are natriuresis, sodium, and diuretics really the good, the bad and the ugly?'The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fractionObesity and natriuretic peptides, BNP and NT-proBNP: mechanisms and diagnostic implications for heart failureImpaired natriuretic and renal endocrine response to acute volume expansion in pre-clinical systolic and diastolic dysfunction.Brain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agentAortocaval fistula in rat: a unique model of volume-overload congestive heart failure and cardiac hypertrophy.Biodesign of a renal-protective peptide based on alternative splicing of B-type natriuretic peptide.B-type natriuretic peptide: beyond a diagnostic.Local renal delivery of a natriuretic peptide a renal-enhancing strategy for B-type natriuretic peptide in overt experimental heart failure.Modulation of cGMP in heart failure: a new therapeutic paradigm.M-atrial natriuretic peptide: a novel antihypertensive protein therapy.Phosphodiesterase type 5 inhibitors and kidney disease.Evolving treatment strategies for management of cardiorenal syndrome.The ASCEND-HF trial: an acute study of clinical effectiveness of nesiritide and decompensated heart failure.PhosphdiesteRasE-5 Inhibition to Improve CLinical Status and EXercise Capacity in Diastolic Heart Failure (RELAX) trial: rationale and design.The tumultuous journey of nesiritide: past, present, and future.Particulate Guanylyl Cyclase A/cGMP Signaling Pathway in the Kidney: Physiologic and Therapeutic Indications.Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure
P2860
Q26853363-5224E2F1-68C3-4100-B00D-229ED49758D8Q27011043-5AD7B13D-5BC8-4CEF-BDFB-ADAA23B3A860Q27024279-3A02C697-BFC7-401B-950A-F91F56F68407Q27027081-93E4B089-B346-4444-AF52-F0ADBFE5E030Q30446941-703AD35D-3149-4F9D-A3A6-CC3764188C1DQ33573360-020D3C53-BE91-406D-B733-92EE57BAEB28Q34512883-E9EA2BA0-9173-4AB3-AA75-97AC843C73D6Q37256856-5C644B5F-D496-406E-9157-1AA0DEC16E7EQ37257355-EFD20ED1-2269-42CB-ACD2-741FA9614932Q37329788-37313886-6D36-490C-9008-503AA3963CBBQ37329891-D6657CDF-920A-48CF-9E21-281B3790F858Q37963837-52D1B317-C499-4FED-9710-5E71BF70B58FQ38560737-89B65145-E0F5-4DF6-AE7F-E5172C7B18C5Q39258545-91663639-546A-485E-9876-2743AD88C7CBQ39609683-59634D25-C8E2-4056-B51A-7081F4DE027FQ41927225-C6EED90A-1EAD-488D-AC01-C999155E4F8EQ43123466-255555A3-69A9-4883-80C1-8261DBEED0C3Q54981618-ED9AF980-5246-49B5-BF15-1942CA3F106FQ57097937-B4BDA769-9EC5-4331-8C6C-27E31FE6E74B
P2860
Maximizing the renal cyclic 3'-5'-guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: a novel strategy to improve renal function in experimental overt heart failure.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 August 2006
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Maximizing the renal cyclic 3' ...... erimental overt heart failure.
@en
Maximizing the renal cyclic 3' ...... erimental overt heart failure.
@nl
type
label
Maximizing the renal cyclic 3' ...... erimental overt heart failure.
@en
Maximizing the renal cyclic 3' ...... erimental overt heart failure.
@nl
prefLabel
Maximizing the renal cyclic 3' ...... erimental overt heart failure.
@en
Maximizing the renal cyclic 3' ...... erimental overt heart failure.
@nl
P2093
P2860
P356
P1476
Maximizing the renal cyclic 3' ...... erimental overt heart failure.
@en
P2093
Alessandro Cataliotti
Brenda K Huntley
Horng H Chen
John A Schirger
John C Burnett
P2860
P304
P356
10.1681/ASN.2006020161
P577
2006-08-23T00:00:00Z